Bryn Mawr Trust CO Zentalis Pharmaceuticals, Inc. Transaction History
Bryn Mawr Trust CO
- $5.44 Billion
- Q4 2024
A detailed history of Bryn Mawr Trust CO transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Bryn Mawr Trust CO holds 1,000 shares of ZNTL stock, worth $1,420. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,000
Previous 1,000
-0.0%
Holding current value
$1,420
Previous $3,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ZNTL
# of Institutions
147Shares Held
65.4MCall Options Held
43.2KPut Options Held
21.7K-
Matrix Capital Management Company, LP Waltham, MA14MShares$19.8 Million2.05% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$6.84 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA4.48MShares$6.35 Million0.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.27MShares$4.65 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.22MShares$4.57 Million0.0% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $80.9M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...